Towards patient-specific tumor antigen selection for vaccination

被引：54

作者：

Rammensee, HG ^{[1
]}

Weinschenk, T ^{[1
]}

Gouttefangeas, C ^{[1
]}

Stevanovic, S ^{[1
]}

机构：

[1] Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany

来源：

IMMUNOLOGICAL REVIEWS | 2002年 / 188卷

关键词：

D O I：

10.1034/j.1600-065X.2002.18815.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this review, we discuss the possibilities for combining the power of molecular analysis of the antigens expressed in a given individual tumor with the design of a tailored vaccine containing defined antigens. Step 1 is a differential gene expression analysis of tumor and corresponding normal tissue. Step 2 is the analysis of human leukocyte antigen (HLA) ligands on tumor cells. Step 3 is data mining with the aim to select those antigens that might be suitable for tumor attack by the adaptive immune system. Step 4 is the on-the-spot clinical grade production of the constituents of the patient tailored vaccine, e.g. peptides. Step 5 is then vaccination and monitoring. Although it will not be possible to cover all relevant antigens expressed in a tumor, the antigens that can be identified with our present technical possibilities might be enough for improved immunotherapy. The scope of the present review is to explore the possibilities and the formidable technical and logistical challenge for such individual patient-oriented antigen definition to be used for therapeutic immunization.

引用

页码：164 / 176

页数：13

共 137 条

[51]

Jäger E, 2000, INT J CANCER, V86, P538

[52]

Kammula US, 1999, J IMMUNOL, V163, P6867

[53] Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein [J].

Karanikas, V ;

Hwang, LA ;

Pearson, J ;

Ong, CS ;

Apostolopoulos, V ;

Vaughan, H ;

Xing, PX ;

Jamieson, G ;

Pietersz, G ;

Tait, B ;

Broadbent, R ;

Thynne, G ;

McKenzie, IFC .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2783-2792

[54] STRICT PEPTIDE LENGTH IS NOT REQUIRED FOR THE INDUCTION OF CYTOTOXIC T-LYMPHOCYTE-MEDIATED ANTIVIRAL PROTECTION BY PEPTIDE VACCINATION [J].

KAST, WM ;

BRANDT, RMP ;

MELIEF, CJM .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (05) :1189-1192

[55] Efficient identification of novel HLA-A*0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis [J].

Kessler, JH ;

Beekman, NJ ;

Bres-Vloemans, SA ;

Verdijk, P ;

van Veelen, PA ;

Kloosterman-Joosten, AM ;

Vissers, DCJ ;

ten Bosch, GJA ;

Kester, MGD ;

Sijts, A ;

Drijfhout, JW ;

Ossendorp, F ;

Offringa, R ;

Melief, CJM .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (01) :73-88

[56] Combined transcriptome and genome analysis of single micrometastatic cells [J].

Klein, CA ;

Seidl, S ;

Petat-Dutter, K ;

Offner, S ;

Geigl, JB ;

Schmidt-Kittler, O ;

Wendler, N ;

Passlick, B ;

Huber, RM ;

Schlimok, G ;

Baeuerle, PA ;

Riethmüller, G .

NATURE BIOTECHNOLOGY, 2002, 20 (04) :387-392

[57] Immunity to oncogenic human papillomaviruses [J].

Konya, J ;

Dillner, J .

ADVANCES IN CANCER RESEARCH, VOL 82, 2001, 82 :205-238

[58] Immune responses to DNA vaccines [J].

Kowalczyk, DW ;

Ertl, HCJ .

CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (05) :751-770

[59] SAGEmap: A public gene expression resource [J].

Lash, AE ;

Tolstoshev, CM ;

Wagner, L ;

Schuler, GD ;

Strausberg, RL ;

Riggins, GJ ;

Altschul, SF .

GENOME RESEARCH, 2000, 10 (07) :1051-1060

[60]

Le Naour F, 2001, PROTEOMICS, V1, P1295

← 1 2 3 4 5 6 7 8 9 10 →